Korsana Biosciences, a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, announced its emergence from stealth, with backing from a leading syndicate of healthcare investors.

The Company was founded in 2024 with a $25 million seed investment from Fairmount and Venrock Healthcare Capital Partners. In September 2025, the Company closed a $150 million private Series A financing co-led by Wellington Management and TCGX, with participation by J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, Foresite Capital, and others. This funding is being used to develop potential best-in-class therapeutics to treat neurodegenerative diseases, with an initial focus on Alzheimer's disease.